BioSpace News Archive

Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, announces that an abstract on the mesothelioma trial has been accepted and will be presented at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting, 9 -14 November 2020.

The rising use of collagen in medical devices and drug delivery systems, increased preference for minimally invasive technologies, and the effectiveness in wound healing are expected to be some of the key factors driving the global demand for collagen in the coming years.

Transgene announced that detailed results of the data from the Phase 1b/2 trial combining TG4001, a HPV16 targeted therapeutic vaccine, with avelumab, a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies, will be presented in a poster presentation at the upcoming virtual meeting of the Society for Immunotherapy of Cancer taking place November 9-14, 2020.

Ultimovacs ASA, announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer.

Akron Biotechnology announced it has signed an agreement with Synairgen plc for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta therapeutic candidate for the treatment of COVID-19 patients.

Calliditas Therapeutics AB announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology Kidney Week 2020 Reimagined conference, to be held virtually October 19-25, 2020.

Designation qualifies Versantis to receive FDA priority review voucher (PRV) upon marketing approval of VS-01

Eurofins U.S. Clinical Diagnostics, announced that Clinical Enterprise Inc. has received an Emergency Use Authorization from the U.S. Food and Drug Administration for their at Home COVID-19 Nasal PCR Test.

The global orthostatic hypotension drugs market is expanding at the back of improvements in blood pressure management tools and equipment.

Healthcare mobility comprises the utilization of various enterprise platforms, applications, and mobile devices to exchange clinical data efficiently and securely and communicate amongst various end users such as patients, providers, and payers.